Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Assessing BioNTech (NasdaqGS:BNTX) Valuation After Founders' Planned Exit And Weakening COVID-19 Revenues
Best Biotech Stocks To Research - March 13th - Markets Daily
Jefferies Financial Group Cuts BioNTech (NASDAQ:BNTX) Price Target to $138.00 - Stock Observer
Is It Time To Reconsider BioNTech (BNTX) After Its Recent Share Price Weakness?
BioNTech (NASDAQ:BNTX) Given Buy Rating at Canaccord Genuity Group - Markets Daily
Is BioNTech (BNTX) Starting To Look Attractive After Recent Share Price Weakness
BioNTech (NASDAQ:BNTX) Given New $94.00 Price Target at TD Cowen - Daily Political
BioNTech's (BNTX) "Buy" Rating Reiterated at Canaccord Genuity Group
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development | Morningstar
BioNTech (NASDAQ:BNTX) Given New $130.00 Price Target at Citigroup
BioNTech (NASDAQ:BNTX) Sees Large Volume Increase - Here's What Happened
TD Cowen Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price
BMO Capital Markets Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX) Receives "Buy" Rating from The Goldman Sachs Group
US Stock Market Today: S&P 500 Futures Edge Lower As Inflation Jitters Linger
BioNTech SE Sponsored ADR $BNTX Shares Sold by Capital International Inc. CA
BioNTech founders to quit roles to start new venture - Türkiye News
BioNTech Founders to Leave Company by 2026 for New mRNA Venture, ETPharma
Clinical development of cancer vaccines
Founders of German vaccine maker BioNTech to step down, lead new firm
Health Care Down Amid Mixed Earnings - Health Care Roundup | Morningstar
BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here?
BioNTech (NASDAQ:BNTX) Given New $138.00 Price Target at Jefferies Financial Group
BioNTech founders to leave, launch new company
BioNTech SE (BNTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue Challenges
Stocks making the biggest moves midday: RIVN, HIMS, KSS, CASY, VRTX
BioNTech founders step down to start new venture - Yahoo News UK
Why BioNTech Stock Is Getting Crushed Today
Analysts' Updated EPS Estimates for March 10th (ADM, ARGX, BNTX, CASY, DAVE, DOM, GFM, KSS, MKS, SBRE) - Daily Political
BioNTech Q4 Earnings Call Highlights | MarketBeat
BioNTech Q4 Earnings Call Highlights - Markets Daily
BioNTech Stock Falls 21% Over Turning To Loss In Q4, Weak FY26 Outlook, Co-Founders Plan To Exit
BioNTech Tumbles as Founding Duo Plan to Leave to Start New Firm
BioNTech (BNTX) Stock Plunges 17% Following Founder Exodus and Disappointing Earnings
BioNTech Slips To Loss In Q4, Warns On Weak FY26 Revenues; Shares Plunge In Pre-market
Scientists behind COVID-19 vaccine will depart BioNTech | Morningstar
BioNTech (NASDAQ:BNTX) Announces Earnings Results, Beats Estimates By $0.18 EPS
Dow Jones Top Company Headlines at 7 AM ET: Bill Ackman's Pershing Square USA Files for IPO | BioNTech ... | Morningstar
BioNTech Repositions From COVID-19 Cash Flows To Oncology-Focused Future
Is BioNTech's (BNTX) Oncology Pivot Rewriting Its Post‑COVID Investment Story?
Assessing BioNTech (BNTX) Valuation After Oncology Pivot And Bristol Myers BNT327 Deal
Is BioNTech SE (BNTX) A Good Stock To Buy Now?
Moderna Settles Patent Dispute for Up to $2.25 Billion, Shares Surge, ETPharma
US Stocks: Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang - The Economic Times
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
Is BioNTech (BNTX) Offering Value After Recent Share Price Weakness?
Moderna agrees to pay up to $2.87 billion to settle Covid-19 vaccine patent dispute
TD Asset Management Inc Trims Holdings in BioNTech SE Sponsored ADR $BNTX - Stock Observer
BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday
BioNTech Stock Forecast | Q4 Results & mRNA Patent Dispute | Capital.com
Primecap Management Co. CA Sells 130,700 Shares of BioNTech SE Sponsored ADR $BNTX - Stock Observer
Pfizer Stock: Is PFE Underperforming the Healthcare Sector?
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of "Moderate Buy" by Brokerages - Markets Daily
Brokerages Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Price Target at $140.10 - Stock Observer
Raiffeisen Bank International AG Has $1.57 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX - Daily Political
BioNTech fires shots at Moderna's next-generation vaccine | Americas | Life Sciences Intellectual Property Review
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
BioNTech Takes Legal Action Against Moderna for COVID Vaccine Patent Infringement, ETPharma
FDA Fast Track Win And New HR Chief Might Change The Case For Investing In BioNTech (BNTX)
BioNTech SE (BNTX) Rallying on Solid Oncology Strategy
Aberdeen Group plc Has $28.79 Million Stock Position in BioNTech SE Sponsored ADR $BNTX
Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC
BioNtech Stock Forecast 2026-2030 | Future Outlook | Capital.com
Bristol-Myers Squibb Resets Pipeline With RNA Deals And Cost Focus
BioNTech News
Adani Total Gas stock (ATGL) surged 37% in two days: What's going on with gas prices?
Starbucks (SBUX) shares analysis: Is Starbucks a good stock to buy right now?
Will Nvidia (NVDA) stock hit $300: What is the NVDA price prediction for 2030?
How to buy the top AI stocks in the Emirates: Microsoft (MSFT), Nvidia (NVDA), Alphabet stock
Most active stocks analysis: NVIDIA (NVDA), Tesla (TSLA), Amazon (AMZN) stock
Latest news
Show moreApple to Lower App Store Commission Fees in China: Strategic Move for Developer Ecosystem Growth
Western Union Unveils Stable Card, Stablecoin Strategy to Combat Inflation
